The integration of bevacizumab improves tumor response and survival in patients with refractory cervical cancer treated with radical chemoradiotherapy

BACKGROUND: Management of refractory cervical cancers (CC) is a debated question and rises dilemma in clinical practice. This study aimed to assess the safety and effectiveness of bevacizumab combined with concurrent chemoradiotherapy in the treatment of refractory CC. METHODS: A total of 129 patien...

Descripción completa

Detalles Bibliográficos
Autores principales: Yang, Hua, Zhang, Ying, Liu, Changhao, Feng, Bin, Zhang, Jianjun, Zhou, Yan, Yin, Yutian, Li, Jianping, Li, Weiwei, Balaya, Vincent, Shi, Mei, Zhao, Lina, Wei, Lichun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8350679/
https://www.ncbi.nlm.nih.gov/pubmed/34430625
http://dx.doi.org/10.21037/atm-21-3521

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8350679/
https://www.ncbi.nlm.nih.gov/pubmed/34430625
http://dx.doi.org/10.21037/atm-21-3521

Ejemplares similares